Protalix BioTherapeutics, Inc. Common Stock (PLX) Stock Price

PLXStock

$2.40+45.18%52W

Market Cap$193.37M

P/E63.20x

PEG Ratio—

Div yield—

Beta-0.11

PLX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-30.37%

Price vs S&P 500 (4W)0.38%

VGM Score65.22

P/E Ratio (Annual)63.20x

P/CF (Annual)21.36x

Book Value / Share (Quarterly)$0.83

Revenue Growth (3Y)3.45%

Cash Flow / Share (Quarterly)$0.16

Price vs S&P 500 (YTD)21.93%

Gross Margin (TTM)69.97%

Net Profit Margin (TTM)20.07%

EPS (TTM)$0.18

10-Day Avg Trading Volume0.87M

EPS Excl Extra (TTM)$0.18

Revenue Growth (5Y)-3.46%

EPS (Annual)$-0.08

ROI (Annual)-13.69%

Gross Margin (Annual)48.82%

Net Profit Margin (5Y Avg)-19.52%

Cash / Share (Quarterly)$0.63

P/E Basic Excl Extra (TTM)12.40x

Revenue Growth QoQ (YoY)233.73%

P/E Normalized (Annual)63.20x

ROA (Last FY)-8.02%

Revenue Growth TTM (YoY)27.80%

EBITD / Share (TTM)$0.26

ROE (5Y Avg)70.52%

Operating Margin (TTM)25.91%

Cash Flow / Share (Annual)$-0.17

P/B Ratio2.83x

P/B Ratio (Quarterly)2.60x

Net Income / Employee (Annual)$-29,200

EV / Revenue (TTM)1.95x

Net Interest Coverage (TTM)-50.93x

ROA (TTM)17.75%

EPS Growth QoQ (YoY)-26.88%

EV / EBITDA (TTM)7.00x

EPS Incl Extra (Annual)$-0.08

Current Ratio (Annual)2.51x

Quick Ratio (Quarterly)2.04x

3-Month Avg Trading Volume0.71M

52-Week Price Return45.18%

EV / Free Cash Flow (Annual)23.22x

P/E Incl Extra (TTM)12.40x

Revenue / Employee (TTM)$338,000

Tangible BV / Share (Quarterly)$0.52

P/S Ratio (Annual)3.61x

Asset Turnover (Annual)0.64x

52-Week High$3.19

Operating Margin (5Y Avg)-13.56%

EPS Excl Extra (Annual)$-0.08

CapEx CAGR (5Y)19.94%

26-Week Price Return-19.13%

Quick Ratio (Annual)1.53x

13-Week Price Return18.72%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.15x

Enterprise Value$149.15M

Revenue / Share Growth (5Y)-20.82%

Asset Turnover (TTM)0.88x

Revenue / Employee (Annual)$233,400

Inventory Turnover (Annual)1.15x

Pretax Margin (Annual)-10.63%

Cash / Share (Annual)$0.38

3-Month Return Std Dev45.58%

Gross Margin (5Y Avg)56.89%

Net Income / Employee (TTM)$67,800

ROE (Last FY)-13.69%

Net Interest Coverage (Annual)27.85x

EPS Basic Excl Extra (Annual)$-0.08

P/FCF (TTM)8.31x

Receivables Turnover (TTM)20.06x

EV / Free Cash Flow (TTM)11.48x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.18

Receivables Turnover (Annual)8.98x

ROI (TTM)28.10%

P/S Ratio (TTM)2.49x

Pretax Margin (5Y Avg)-18.38%

Revenue / Share (Annual)$0.67

Tangible BV / Share (Annual)$-0.20

Forward P/E11.00x

Price vs S&P 500 (52W)26.87%

P/E Ratio (TTM)12.40x

EPS Growth TTM (YoY)638.87%

Year-to-Date Return33.89%

5-Day Price Return2.99%

EPS Normalized (Annual)$-0.08

ROA (5Y Avg)-11.67%

Net Profit Margin (Annual)-12.52%

Month-to-Date Return1.69%

Cash Flow / Share (TTM)$0.18

EBITD / Share (Annual)$-0.05

Operating Margin (Annual)-10.43%

LT Debt / Equity (Annual)6.61x

P/CF (TTM)12.60x

ROI (5Y Avg)-23.85%

P/E Excl Extra (TTM)12.40x

LT Debt / Equity (Quarterly)0.52x

EPS Basic Excl Extra (TTM)$0.18

P/TBV (Quarterly)2.73x

P/B Ratio (Annual)3.00x

Inventory Turnover (TTM)0.92x

Pretax Margin (TTM)25.22%

Book Value / Share (Annual)$0.60

Price vs S&P 500 (13W)15.93%

Beta-0.11x

P/FCF (Annual)25.72x

Revenue / Share (TTM)$0.92

ROE (TTM)28.10%

52-Week Low$1.52

vGradeB

gGradeB

mGradeB

vgmGradeB

PLX Earnings Surprise History

Q2 250.00est. 0.03

Q3 250.03est. 0.06

Q4 25-0.07est. 0.01

Q1 260.22est. -0.01

Q2 260.05est. -0.01

PLX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
PLXProtalix BioTherapeutics, Inc. Common Stock	B	B	B	$2.40
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Protalix BioTherapeutics, Inc. Common Stock

Protalix BioTherapeutics develops recombinant therapeutic proteins using its proprietary ProCellEx platform to treat rare lysosomal storage and genetic diseases, including Gaucher disease, Fabry disease, and cystic fibrosis. Revenue comes from product sales in Brazil and a manufacturing supply agreement with Pfizer. The company's pipeline includes ELFABRIO, Uricase, and Long Acting DNase I.